Fluorescein

Fluorescein

SCHEMBL1899996

CCCCC(=O)O.O=C1OC2(c3ccc(O)cc3Oc3cc(O)ccc32)c2ccccc21

nearest known ligand 0.72

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FTO Q9C0B1 10/20 0.72
▸ MAPT P10636 4/20 0.72
▸ MEN1 O00255 3/20 0.72
▸ KMT2A Q03164 3/20 0.72
▸ HTT P42858 2/20 0.72
▸ HPGD P15428 2/20 0.72
▸ TDP1 Q9NUW8 2/20 0.72
▸ CYP2C19 P33261 1/20 0.72
▸ RECQL P46063 1/20 0.72
▸ BLM P54132 1/20 0.72
▸ SMAD3 P84022 1/20 0.72
▸ PRMT1 Q99873 1/20 0.72
▸ ACE2 Q9BYF1 1/20 0.72
▸ LMNA P02545 3/20 0.55
▸ ALOX12 P18054 2/20 0.55
▸ GPR55 Q9Y2T6 2/20 0.55
▸ POLB P06746 1/20 0.55
▸ NPSR1 Q6W5P4 1/20 0.55
▸ CYP3A4 P08684 2/20 0.55
▸ ALDH1A1 P00352 3/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Fluorescein SCHEMBL3866853 0.97 FTO (0.70) FTOMAPTMEN1KMT2AHTT
Fluorescein SCHEMBL19128333 0.96 FTO (0.69) FTOMAPTMEN1KMT2AHTT
Fluorescein SCHEMBL20764877 0.96 FTO (0.69) FTOMAPTMEN1KMT2AHTT
Fluorescein SCHEMBL5886626 0.96 FTO (0.69) FTOMAPTMEN1KMT2AHTT
Fluorescein SCHEMBL14776969 0.96 FTO (0.69) FTOMAPTMEN1KMT2AHTT
Fluorescein SCHEMBL27939701 0.96 FTO (0.69) FTOMAPTMEN1KMT2AHTT
Fluorescein SCHEMBL10388070 0.93 FTO (0.75) FTOMAPTMEN1KMT2AHTT
Fluorescein SCHEMBL27157742 0.92 FTO (0.77) FTOMAPTMEN1KMT2AHTT
Fluorescein SCHEMBL27157745 0.91 FTO (0.75) FTOMAPTMEN1KMT2AHTT
Fluorescein SCHEMBL27395251 0.91 FTO (0.82) FTOMAPTMEN1KMT2AHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110177619-A1 IN VITRO DIAGNOSTIC MARKERS COMPRISING CARBON NANOPARTICLES AND KITS PITLAB LTD (GB) 2011-07-21 — — US disclosed
EP-2318051-A2 IN VITRO DIAGNOSTIC MARKERS COMPRISING CARBON NANOPARTICLES AND KITS Metters, Andrew (US) 2011-05-11 — — EP disclosed
WO-2010008519-A2 IN VITRO DIAGNOSTIC MARKERS COMPRISING CARBON NANOPARTICLES AND KITS METTERS ANDREW (US) 2010-01-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110177619-A1 IN VITRO DIAGNOSTIC MARKERS COMPRISING CARBON NANOPARTICLES AND KITS CD63, LGALS3, MKI67 FTO 326/4885MAPT 3166/4885MEN1 2546/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback